Morningside Ventures leads Series A round for DeepCure

DeepCure, a developer of small molecule therapeutics, has raised $40 million in Series A financing.

DeepCure, a developer of small molecule therapeutics, has raised $40 million in Series A financing. Morningside Ventures led the round with participation from existing investors TLV Partners, Sapir Venture Partners, and Benon Group Ltd.

Source: Press Release